2014
Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000-2008
PAVLÍK, Tomáš, Ondřej MÁJEK, Tomáš BÜCHLER, Rostislav VYZULA, Jiří PETERA et. al.Základní údaje
Originální název
Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000-2008
Autoři
PAVLÍK, Tomáš (203 Česká republika, garant, domácí), Ondřej MÁJEK (203 Česká republika, domácí), Tomáš BÜCHLER (703 Slovensko), Rostislav VYZULA (203 Česká republika), Jiří PETERA (203 Česká republika), Miroslav RYŠKA (203 Česká republika), Aleš RYŠKA (203 Česká republika), David CIBULA (203 Česká republika), Marek BABJUK (203 Česká republika), Jitka ABRAHAMOVÁ (203 Česká republika), Jiří VORLÍČEK (203 Česká republika), Jan MUŽÍK (203 Česká republika, domácí) a Ladislav DUŠEK (203 Česká republika, domácí)
Vydání
Cancer epidemiology, Oxford, Elsevier, 2014, 1877-7821
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30200 3.2 Clinical medicine
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 2.711
Kód RIV
RIV/00216224:14110/14:00075537
Organizační jednotka
Lékařská fakulta
UT WoS
000334029800005
Klíčová slova anglicky
Cancer; Population-based registry; Relative survival; Stage-specific analysis
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 22. 5. 2014 12:26, Soňa Böhmová
Anotace
V originále
Background: The objective of this study was to assess trends in overall and in stage-specific 5-year relative survival rates of the Czech cancer patients between periods 2000-2004 and 2005-2008. Methods: All Czech cancer patients diagnosed between 1995 and 2008 were included in the analysis. Period analysis was employed to calculate 5-year relative survival for 21 cancers. Results: Significant improvements in crude 5-year relative survival for 14 of 21 assessed types of cancer, including the most frequent diagnoses, such as, colorectal, prostate, breast, lung, kidney, pancreatic, and bladder cancer and melanoma, were identified. Moreover, in case of colorectal, lung, and prostate cancer, improvement in stage-specific 5-year relative survival was confirmed as statistically significant for all clinical stages. No diagnosis showed significant decrease in the 5-year relative survival. However, the 5year relative survival remained poor in patients with metastatic cancers at diagnosis, particularly in case of liver, pancreatic, lung, and oesophageal cancer. Conclusions: The cancer-specific outcomes in the Czech Republic are improving. Nevertheless, despite the overall significant improvement in 5-year relative survival of most of the cancer diagnoses, the high proportion of patients primarily diagnosed with metastatic cancer still represents a substantial challenge for prevention and early detection.
Návaznosti
MUNI/A/0828/2011, interní kód MU |
|